Crusekitug

鲁塞奇塔单抗

Report date: 2026/05/26 20:00:28

Base Information

Drug NameCrusekitug
Drug Alias Name重组人源化抗IL-17A单克隆抗体注射液QX-002N
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin 17A inhibitors
TargetsInterleukin 17A
Therapy Area/IndicationsSpondylitis, Ankylosing
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesQyuns Therapeutics Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJiangsu Saifushi Biotechnology Co LtdQyuns Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsSpondylitis, Ankylosing
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A